Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Viral Shedding Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding

NCT04478019
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Sep 25, 2026, 4:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

RSV Challenge in Healthy Adults

NCT00100373
View directory record Official record
Conditions
Respiratory Infections, Acute, Respiratory Syncytial Virus
Interventions
RSV challenge material
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 25, 2026, 4:55 PM EDT
Completed No phase listed Observational

Evaluation of Viral Shedding Patterns and Clinical Outcomes of Influenza Patients

NCT01839760
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Sep 25, 2026, 4:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding

NCT00803543
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Sep 25, 2026, 4:55 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children

NCT00767416
View directory record Official record
Conditions
Healthy
Interventions
MEDI-559, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Month to 23 Months
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
75
States / cities
Greenville, Alabama • Huntsville, Alabama • Mobile, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Sep 25, 2026, 4:55 PM EDT
Completed No phase listed Observational

Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults

NCT00998803
View directory record Official record
Conditions
Influenza Virus
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Sep 25, 2026, 4:55 PM EDT
Completed Phase 4 Interventional

A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons

NCT00161434
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
valacyclovir, placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 9, 2008 · Synced Sep 25, 2026, 4:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

The Compartmental Biology of HIV in the Male Genital Tract

NCT02638493
View directory record Official record
Conditions
Human Immunodeficiency Virus, Virus Shedding
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2017 · Synced Sep 25, 2026, 4:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis

NCT01533480
View directory record Official record
Conditions
Keratoconjunctivitis Due to Adenovirus, Viral Shedding
Interventions
Zirgan, genteal gel
Drug
Lead sponsor
Lifelong Vision Foundation
Other
Eligibility
14 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 25, 2026, 4:55 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers Results available

A Study to Evaluate AAV9 Neutralizing Antibody Seroconversion in Household Contacts.

NCT04543357
View directory record Official record
Conditions
Household Contacts
Interventions
Blood Draw
Other
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Sep 25, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)

NCT00192387
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T, Liquid
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 18 Months
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Monroe, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Sep 25, 2026, 4:55 PM EDT
Terminated Phase 4 Interventional Results available

A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain

NCT01032837
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
100
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Sep 25, 2026, 4:55 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes

NCT04832932
View directory record Official record
Conditions
COVID-19 Vaccines
Interventions
COVID-19 vaccines
Biological
Lead sponsor
Mebo Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
2
States / cities
Miami, Florida • Vonore, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Sep 25, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine

NCT04811664
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Moderna COVID-19 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 29 Years
Enrollment
1,923 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
51
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Sep 25, 2026, 4:55 PM EDT
Not listed Phase 2 Interventional

Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19

NCT04911777
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Pentarlandir™ UPPTA, Placebo
Drug
Lead sponsor
SyneuRx International (Taiwan) Corp
Industry
Eligibility
18 Years to 64 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Cullman, Alabama • Gilbert, Arizona • Bradenton, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Sep 25, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)

NCT04405739
View directory record Official record
Conditions
SARS-CoV 2
Interventions
EIDD-2801, Placebo
Drug
Lead sponsor
Ridgeback Biotherapeutics, LP
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Los Angeles, California • Chicago, Illinois • Oak Lawn, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 25, 2026, 4:55 PM EDT
Completed No phase listed Observational Results available

Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture

NCT01878383
View directory record Official record
Conditions
Herpes Simplex Virus
Interventions
Genexpert assay
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
12,550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 25, 2026, 4:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

NCT00116844
View directory record Official record
Conditions
Infections, Herpesviridae
Interventions
Valaciclovir, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
17
States / cities
Carmichael, California • Davis, California • Riverside, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Sep 25, 2026, 4:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

NCT00345670
View directory record Official record
Conditions
Healthy
Interventions
MEDI-534
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Year to 9 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
12
States / cities
Fountain Valley, California • Shawnee, Kansas • Topeka, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2008 · Synced Sep 25, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

NCT01687595
View directory record Official record
Conditions
Herpes Simplex Type 2
Interventions
HerpV and QS-21, Placebo
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Portland, Oregon • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 25, 2026, 4:55 PM EDT
Completed Phase 4 Interventional

A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding

NCT00129818
View directory record Official record
Conditions
Genital Herpes
Interventions
Famciclovir
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Timeline
2004 – 2005
U.S. locations
7
States / cities
Birmingham, Alabama • Orlando, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Sep 25, 2026, 4:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study

NCT00464542
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 25, 2026, 4:55 PM EDT
Withdrawn No phase listed Observational

Pharmacokinetics, Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and Raltegravir

NCT01597180
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
20 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 25, 2026, 4:55 PM EDT